{"id":"W4413318599","doi":"10.1007/s10637-025-01573-0","title":"Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Colorectal cancer; Triple-negative breast cancer; Internal medicine; Oncology; Breast cancer; Metastatic breast cancer; Open label; Cancer; Cancer research; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001671909,0.001862996,0.001855924,0.0002703165,0.0006798623,0.0008685435,0.0008604894,0.001729253,0.006387745],"category_scores_gemma":[0.00122583,0.001178863,0.001183898,0.0002310352,0.0008095826,0.001087637,0.0003938458,0.003837643,0.001543631],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008031467,"about_ca_system_score_gemma":0.001788597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00119299,"about_ca_topic_score_gemma":0.004441707,"domain_scores_codex":[0.9995933,0.0001648376,0.00001976932,0.0001069831,0.00004004205,0.00007508808],"domain_scores_gemma":[0.9993532,0.0001003819,0.0001265871,0.0000454734,0.00009343483,0.0002808274],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8132131,0.1166951,0.00419278,0.001123721,0.001725808,0.0001635047,0.0003388469,0.0005831783,0.02458747,0.0002633152,0.004315495,0.03279791],"study_design_scores_gemma":[0.6858847,0.3017656,0.006442414,0.0000457501,0.0006301841,0.0001225327,0.00009537233,0.0004955782,0.001175415,0.0003145413,0.002997991,0.00002993134],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791753,0.001985261,0.001027223,0.0007202056,0.0003615213,0.01199558,0.002140467,0.0001441062,0.002450318],"genre_scores_gemma":[0.9632921,0.001821493,0.003788732,0.002384606,0.0003431415,0.01964715,0.002358208,0.00004758401,0.006317007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006387745,"threshold_uncertainty_score":0.0213691,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05132265043575454,"score_gpt":0.3734473502891841,"score_spread":0.3221246998534295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}